- Home
- PMVP vs ONCY Comparison
PMVP vs ONCY Comparison
Compare PMVP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ONCY
- Stock Information
- Founded
- PMVP 2013
- ONCY 1998
- Country
- PMVP United States
- ONCY Canada
- Employees
- PMVP N/A
- ONCY N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PMVP Health Care
- ONCY Health Care
- Exchange
- PMVP Nasdaq
- ONCY Nasdaq
- Market Cap
- PMVP 55.1M
- ONCY 49.1M
- IPO Year
- PMVP 2020
- ONCY 1999
- Fundamental
- Price
- PMVP $1.06
- ONCY $0.77
- Analyst Decision
- PMVP Strong Buy
- ONCY Strong Buy
- Analyst Count
- PMVP 1
- ONCY 4
- Target Price
- PMVP $5.00
- ONCY $4.33
- AVG Volume (30 Days)
- PMVP 283.2K
- ONCY 1.2M
- Earning Date
- PMVP 08-07-2025
- ONCY 07-31-2025
- Dividend Yield
- PMVP N/A
- ONCY N/A
- EPS Growth
- PMVP N/A
- ONCY N/A
- EPS
- PMVP N/A
- ONCY N/A
- Revenue
- PMVP N/A
- ONCY N/A
- Revenue This Year
- PMVP N/A
- ONCY N/A
- Revenue Next Year
- PMVP N/A
- ONCY N/A
- P/E Ratio
- PMVP N/A
- ONCY N/A
- Revenue Growth
- PMVP N/A
- ONCY N/A
- 52 Week Low
- PMVP $0.81
- ONCY $0.33
- 52 Week High
- PMVP $1.82
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- PMVP 52.88
- ONCY 70.82
- Support Level
- PMVP $1.01
- ONCY $0.56
- Resistance Level
- PMVP $1.12
- ONCY $0.77
- Average True Range (ATR)
- PMVP 0.08
- ONCY 0.09
- MACD
- PMVP -0.00
- ONCY 0.02
- Stochastic Oscillator
- PMVP 23.26
- ONCY 88.51
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.